SciSparc Subsidiary NeuroThera Labs Gets Conditional TSX Approval for 54% CliniQuantum Acquisition

SciSparc Ltd. announced that its majority‑owned subsidiary NeuroThera Labs has received conditional regulatory approval from the TSX Venture Exchange for the acquisition of about 54% of CliniQuantum Ltd.

NeuroThera will issue 56.6 million of its common shares, valued at approximately $9.46 million (based on a 20‑day volume‑weighted average price), to acquire the 54% stake in CliniQuantum.

The deal includes potential earn‑out payments of up to $2.5 million payable over three years, contingent on patent‑filing and fundraising milestones.

Closing is contingent on final regulatory sign‑offs, including an Israeli tax ruling and final TSX Venture Exchange acceptance, with an outside date extended to June 1, 2026.